Pathologica pulmonis cancer immunotherapy, lung cancer immunotherapy, lung cancer PD-1 treatment, and lung cancer PD-L1 treatment are all you want to know.
In the past two years, immune checkpoint inhibitors have undoubtedly been one of the most successful tumor immunotherapies, which has changed the treatment prospects for NSCLC. The four PD-1 / L1 currently approved for lung cancer have improved the five-year survival rate of advanced lung cancer from less than 5% to 16%, which has tripled, and many patients and even doctors are excited. Immunotherapy is gradually becoming a “special effect” drug for the treatment of advanced cellula parva non-pulmonis cancer. Most pulmonis cancer, patients still have many questions about PD-1 treatment, and today we will answer them one by one.
Quod PD-I / L1 curatio pulmonis cancer?
Immunotherapy is a therapy that uses the patient’s immune system to fight cancer. PD-1 / L1 treatment is called immune checkpoint inhibitor therapy and is a type of immunotherapy.
Immune checkpoint inhibitor therapy refers to: PD-1 is a protein on the surface of T cells that helps control the body’s immune response. When PD-1 binds to another protein called PDL-1 on cancer cells, it prevents T cells (an immune cell) from killing cancer cells. The PD-1 inhibitor binds to PDL-1, thereby releasing the immune suppression of T cells and regaining the ability to kill cancer cells
Quid sunt current PD-I / L1 probatus per FDA ad curatio pulmonis cancer?
The FDA approved four immune checkpoint inhibitors: Nivolumab (O drug), pembrolizumab (K drug), atezolizumab (T drug) and durvalumab (I drug) for the treatment of non-small cell lung cancer.
| nomen medicamento | Pembrolizumab | Nivolumab | Attuzumab | Devaruzumab |
| nomen anglicus | keytruda | Mirabilis | Tecentriq | Imfinzi |
| fabrica | Merck Poland | Londini, Myers | petram | AstraZeneca |
| dosis | 2mg / kg iterum in tres septimanas | 3mg / kg omnis duo weeks semel, | Cum omnes tres hebdomades 1200mg | 10mg / kg omnis duo weeks semel, |
| Listing | US album | enumerantur in Sinis | US album | Enumerantur in Sina |
Quae enim sunt signa pulmonis cancer inter se I-PD / L1 probat?
Pabolizumab (Pembrolizumab, Pambrolizumab, Pembrolizumab) | Da Kerui (Jinheide, Keytruda) | K pharmacum
| Signa probatus (pulmonis cancer) | Utrum deprehendere PD-L1 |
| 1. deducta pemetrexed et cisplatin / curatio est recta, primum quia Carboplatin unresectable, provectus / squamosa ossis temporalis non-non-relapsus est parva cellula pulmonis cancer (NSCLC) aegris, regardless of PD-L1 expressio | nihil |
| 2. deducta Carboplatin et paclitaxel /-nab paclitaxel (Abraxane) pro cum aegris provectus / recurrentes squama cellula parva non-pulmonis cancer (NSCLC) ab hoc primum effectum, non potest esse recta curatio, regardless of PD-L1 expressio | nihil |
| 3. Single-agent, first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC), whose metastatic non-small cell lung cancer (NSCLC) tumors have high PD-L1 expression [tumor proportion score (TPS) ≥50%], by FDA approved test confirms that there are no EGFR or ALK genome tuberculum plerarumque aberrationum | Ita PD-L1≥50% |
| 4. Single drug treatment for patients with metastatic non-small cell lung cancer (NSCLC), whose tumor expresses PD-L1 ((TPS) ≥ 1%), determined by FDA approved trials, disease progression after platinum-based chemotherapy | Ita PD-L1 ≥ I% |
Nivolumab (Navumab, Niluumab, Nivolumab) | Odivo (Odivo, Odvo, Opdivo) | Domine medicamento
| Signa probatus (pulmonis cancer) |
| 1. Nam de curatio provectus (metastatic) cellula parva non-pulmonis cancer, quae coniunctiones platini adhuc subit chemotherapy |
| 2. Nam curatio de patientibus proficiebat (metastatic) squama cellula parva non-pulmonis cancer (NSCLC) idoneam platinum-fundatur pro aegris qui chemotherapy quorum morbum, vel deterioratus cum chemotherapy |
Devarizumab (Duvaluzumab, Duvalizumab, Deluzumab, Durvalumab) | Ego medicamento (Imfinzi)
| Signa probatus (pulmonis cancer) |
| Hoc est parva cellula solebat tractare, non-localis provectus pulmonis cancer (NSCLC) quae manu redditur, non quod perpessa resection platinum-fundatur, post vexillum simul radiochemotherapy |
Attuzumab (Atezolizumab, Atezolizumab) | T medicamento (Tecentriq)
| Signa probatus (pulmonis cancer) |
| 1. Metastasico cellula parva non-pulmonis cancer, quarum conditio deterior durante vel post-platinum quibus chemotherapy. Si patientes in cellula parva non-pulmonis cancer mutationes in EGFR ALK vel genes, Dicotyledones venenum gene mutationes ALK targeting EGFR aut debet esse primus, etc. Attuzumab |
| 2. deducta chemotherapy (Abraxane [paclitaxel dapibus major;-nab paclitaxel] et Carboplatin) in prima acie-curatio non-parva squama-cell non metastatic aegris cum pulmone cancer (NSCLC) vel sine EGFR ALK |
Quam eligere PD-I / L1 cum pulmone cancer aegris
Quam ad eligere unum de quatuor maxime sollicitus sit immunis LAPIS inhibitors problems pulmonis cancer aegris. Summatim in hoc tables arbitrium medicamento consilium et detail in omnes evidenter.
Mutationem libero, non-parva cellula pulmonis cancer
Primam aciem processit ad pulmonis cancer immunotherapy
| Dolor | Primo gradu, commendaticiis | Level III commendaticiis |
| PD-L1≥50% | Pembrolizumab MONOTHERAPY | |
| ≤PD L1≤1,% I% | Plattenepithelkarzinom: Pabolizumab
Non Plattenepithelkarzinom: Pabolizumab uno aut medicamento Pabolizumab combined per coniunctiones platini pemetrexed + |
|
| PD-L1 <I% vel ignotum | Non Plattenepithelkarzinom: paclizumab combined per coniunctiones platini pemetrexed + | Non-squamous cell carcinoma: atezumab combined with bevacizumab combined with chemotherapy (carboplatin and paclitaxel) |
Deinde versus pulmonis cancer immunotherapy provectae
| Dolor | Primo gradu, commendaticiis | Level III commendaticiis |
| Nulla prior PD-I / L1 curatio | PD-L1 ignota est expressio vel cujuscumque status, nivolumab MONOTHERAPY | PD-L1 ignota est expressio vel sine status: atezumab MONOTHERAPY |
| Prior PD-I / L1 curatio | Prior PD-I / L1 precursor curatio: contentus debet compositae cum chemotherapy coniunctiones platini (eligere oportet quod chemotherapy histological secundum genus)
Prior PD-I / Lorem L1 precursor combined cum chemotherapy, docetaxel, una agente vel chemotherapy (prima acie irreceptum, medicinae VI) |
Tertiam aciem immunotherapy provectae pulmonis cancer: secundario commendatione nivolumab.
Three-stage unresectable non-small cell lung cancer: Grade III recommendation, receiving consolidation therapy with dufaliolizumab after radiotherapy and chemotherapy.
Non parva mi
cum pulmone cancer mutationem
Nam cum immunotherapy de NSCLC EFGR positivum / ALK, est tamen quaedam feruntur. Subgroup analysis in sequentibus studium IMpower150 eventus ostendere, qui rationem non habet modum certum: atelizumab bevacizumab + + + Carboplatin Spermatophyta
Quid opus sit probata coram Indicatores PD-usura I / L1?
Hoc tempore, clinicians ad in PD-L1, sicut expressio VUL limites figunt, ad pulmonem immunotherapy et chemotherapy. Rossy articulus est compilavit in vobis: ut indicarent regi quinque biomarkers venturam dicunt, quod virtus I-PD. Et potest referri ad: venturam dicunt, quid vis ut pre PD-I? A analysis de quinque major comprehensive Predictors!
I) PD-L1
Hoc tempore, considerandum est quod expressio PD-L1 in tumore magis est rationabile etiam textus venalicium pro lectio una dominatur in conspectu populi I-anti-PD / PD-L1 curatio. Sed simul multa problemata deprehendatur L1-PD ut heterogeneum localia possunt modico tumore totius civitatis personam totius tumor? Est etiam temporalia Heterogenei Luminis, quia post curatio, PD-L1 est quod expressio non mutare statum. Non est standardization immunohistochemical deprehendatur. Sunt plures ibi elementorum ad PD-L1 immunohistochemical tinguere. In rate of positivum pactum ibi elementorum est aliud nisi LXXIII% -1%, quod afficit et tremorum results.
II) VULA
Current investigationis ostendit quod VULA / icis bTMB in predictive titulum de medicinales effectus est etiam controversiae.
Sicut enim qui domesticas aegris qui sunt diagnosed cum non-parva cellula provectus pulmonis cancer, pulmonis cancer curatio in industria plerumque domesticis commendat PD-L1 test. Si PD-L1 ≥ L%, utrum sit Plattenepithelkarzinom aut ministro acatholico attentarunt Plattenepithelkarzinom, nuper tractaretur, non-gene mutationem non-parva cellula pulmonis cancer aegris potest esse tractata sunt K medicinae ad consequi summa salute beneficium, nunc.
Scilicet, per applicationem autem orci tuta LAPIS inhibitors, Civitatibus Foederatis Americae est maxime pervestigandam et orci in occultis habet experientiam. In Civitatibus Foederatis Americae pars auctoritate experts pulmone cancer sunt fundatur in current notitia VUL in PD-L1 de chemotherapy et / vel immunotherapy de pulmone cancer sunt stratified aegroti.
1. anti-PD-I MONOTHERAPY datum est aegris cum "aestus" et panos in excelsis et in PD-L1 expressio VUL.
2. cum enim aegris excelsum et humilis VUL PD-L1 expressio, chemoimmunotherapy dare.
3. Nam his aegris cum princeps vel humilis, sed negans VUL PD-L1 sonaturum, des nominis chemoimmunotherapy aut anti-PD-I / IV-Lorem CTLA.
4. Praeterea, aegris cum "frigus" vel non-inflammatione in secretiori parte natium et humilis humilem nec negans VUL PD-L1 expressio, chemotherapy est ab eis vel non potest aut immunotherapy cellular immunotherapy.
Rossy commemorat maioris de pulmone cancer aegris, quod prius per PD-I, quod est eligere haud dubio auctore probatum turba quia biomarker tentationis, et tunc consuleret Bei Shangguang vel a well-known pulmonis cancer peritus in Civitatibus Foederatis Americae habuerit edisserere precise medicamento consilium aut posse a global oncologist consuleret. Web Department of Medicine.
PD-I cum aegris can expressio uti humilis-PD I?
Nam qui patientibus proficiebat non-parva cell carcinoma, qui iusti esse dignoscitur, sicut dum PD-L1 expressio fuerit affirmativa, utrum sit Plattenepithelkarzinom aut ministro acatholico attentarunt Plattenepithelkarzinom est, sit possibile vel salvos beneficia ab initial K-medicamento curatio de MONOTHERAPY, ita extensio vitae. Etiam periti suadeant ut aliqua aegris in PD-L1 expressio inter K 1-49% plus chemotherapy utuntur si potes sustinere potest chemotherapy.
PD-I can exsisto adsuesco assuesco aegris nuper tractata negans in PD-L1 test?
Recentes eventus plures PD-I, Klon combined chemotherapy studiis comprobasse, ut si PD-L1 test esse negans, vel PD-L1 non probata sub conditione, PD-I, Klon combined cum chemotherapy potest tractare Plattenepithelkarzinom aut ministro acatholico attentarunt squamosa ossis temporalis cell carcinoma. Cellular pulmonis cancer aegris producat amplius beneficia salvos cum chemotherapy solum significant.
Enim aegris in PD-L1-negans non-parva cellula pulmonis cancer, sive habent squama aut ministro acatholico attentarunt squamosa ossis temporalis non-parva cellula pulmonis cancer, si quod non suscepit chemotherapy in conspectu post accepto K combined chemotherapy, comparari cum chemotherapy solus Omnia iam salvos aegris can adepto a bonum. Quae data est bonum nuntium pro illis aegris est expressio vel negans PD-L1-L1 nulla ratione PD ad deprehendere.
Passio aegris can vel switch chemotherapy addendi PD-I?
Cujuscumque utrum sit an non squama squama-cell parva non-pulmonis cancer, effectus chemotherapy est certus melius quam K combined cum chemotherapy solum, sed aegris potest accipere chemotherapy quae accipientes I-PD, Klon? Quod effectus chemotherapy est melius?
Post Rectum et chemotherapy est, occidere de tumore cellulis, ita tumore dimittit antigens humana immunitatem, animos excitante. In hoc, si PD-curatio I, Klon datum est, in motu violento, in anti-tumore effectus erit fortior. Hoc tempore sunt, quae praevia eventus investigationis ostendit quod sustentacionem immune curatio I, Klon in PD-L1-PD vel post, Klon simultaneous Rectum et chemotherapy est significantly quodammodo continuare vitam et bonum effectus.
Qui mox ut fuerit diagnosed aegris incipit chemotherapy primum annota, deinde I-PD eligere vel directe usum PD-I cum medicamento resistentia,
Nam cellula parva non-cancer patientibus proficiebat his tantum qui sunt diagnosed, uti primis in PD-I, Klon salvos beneficia meliora adducere, quam nuper usus.
Quod cum facere-PD I resistentia?
Et plerumque I-PD efficaciora sunt aegroti inhibitors DIUTURNUS effectus; sed de XXX% de aegris ipsi, ut morbo resistentia. Superandae resistentiae medicamento quod maxime key puncta duo:
Primum, si fieri potest, biopsy et immunes altius analysis situs potest fieri in nuper additae medicamento resistentia et augendae causa ut ad medicamento resistentia et facies secundum causam. Exempli gratia, aliqui sint ex compensatory aegris excelsum-expressio Tim III, III-TARDO seu IDO; igitur eligere, PD-I ad Tim combined Matrix-III inhibitor-III TARDO antibody, IDO precursor est optimus treatment solutions.
Secundo, quia et aegris potest determinare causa medicamento resistentiam, discurrat ipsam certis conditionibus optimum eligere socium ad iuncturam salvos adversa medicamento resistentia et per patientiam sustentatur; vel, ut mutes rationem tuam traditional treatments Rectum et chemotherapy, non extrinsecus, radio frequency et particulam implantationem.
Denique ac potissimum, quod subsidia, quod magis ac magis immunotherapy ut PD-I inhibitors debet adhiberi ut mane fieri potest bonum est conditio generalis est, ubi supinus aeger summo tumore effundunt, et onus non sit ita magnus.
